Bortenat Injection

Bortezomib
2mg
Getwell Pharmaceuticals
Pack size
Dispensing mode
Source
Agent
Retail Price

Available as:

Indications

Bortenat Injection is used for: Multiple Myeloma, Mantle Cell Lymphoma

Adult Dose

Mantle Cell Lymphoma Indicated for the treatment of patients with mantle cell lymphoma as first-line in previously untreated patients or those who have relapsed Previously untreated MCL 1.3 mg/m²/dose IV twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) for six 3-week cycles; may continue for 8 cycles if response is first seen at cycle 6 Give with rituximab 375 mg/m² IV, cyclophosphamide 750 mg/m² IV, and doxorubicin 50 mg/m² IV on day 1, plus prednisone 100 mg/m² IV on days 1-5 Relapsed MCL 1.3 mg/m²/dose IV/SC twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) Therapy extending beyond 8 cycles: Give standard schedule Multiple Myeloma Previously untreated multiple myeloma Administer in combination with prednisone and melphalan as part of 6-wk treatment cycles for 9 cycles Cycles 1-4 (twice weekly): 1.3 mg/m² IV/SC on Days 1, 4, 8, 11, 22, 25, 29, and 32 Cycles 5-9 (once weekly): 1.3 mg/m² IV/SC on Days 1, 8, 22, and 29 Relapsed multiple myeloma 1.3 mg/m²/dose IV/SC twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21) Therapy extending beyond 8 cycles: Standard schedule or maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35) Retreatment Indicated for retreatment of adults with multiple myeloma who had previously responded to bortezomib and relapsed at least 6 months following completion of prior bortezomib treatment Treatment may be started at the last tolerated dose Administer twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) Hepatic impairment Moderate-to-severe (bilirubin >1.5x ULN): Reduce to 0.7 mg/m² in the first cycle; consider dose escalation to 1 mg/m² or further dose reduction to 0.5 mg/m² in subsequent cycles based on tolerability

Child Dose

Renal Dose

Administration

Preparation Reconstitute vial with 0.9% NaCl IV administration: Add 3.5 mL to vial for final concentration of 1 mg/mL SC administration: 2.5 mg/mL: Add 1.4 mL to vial for final concentration of 2.5 mg/mL If local injection site reactions occur following SC administration, a less concentrated solution (1 mg/mL) may be administered subcutaneously IV or SC administration Not for intrathecal (IT) use; inadvertent IT has resulted in death and is contraindicated Separate consecutive doses by at least 72 hr Give IV as a bolus over 3-5 seconds or as SC injection Give SC injection in thigh or abdomen; rotate injection site with each dose Monitor hydration status Use cytotoxic handling procedures for preparation, administration, and disposal

Contra Indications

Hypersensitivity. Child. Pregnancy and lactation.

Precautions

Hepatic or renal impairment; history of syncope, orthostatic hypotension; dehydration. Impairs ability to drive or operate machinery. Monitor for symptoms of peripheral neuropathy. Monitor closely the blood glucose levels in patients receiving oral antidiabetic agents.

Pregnancy-Lactation

Interactions

Concurrent use of amiodarone, antivirals, isoniazid, nitrofurantoin, statins may increase the chance of peripheral neuropathy. Concurrent use of antihypertensives increases the chance of hypotension.

Adverse Effects

Side effects of Bortezomib : >10% Asthenia (61-65%) Nausea (61-65%) Diarrhea (51-55%) Anorexia (41-45%) Constipation (41-45%) Thrombocytopenia (41-45%) Peripheral neuropathy (IV: 16-41%; SC: 6-24%) Pyrexia (36-40%) Vomiting (36-40%) Anemia (31-35%) Arthralgia (26-30%) Headache (26-30%) Insomnia (26-30%) Limb pain (26-30%) Dizziness (21-25%) Dyspnea (21-25%) Edema (21-25%) Neutropenia (21-25%) Paresthesia (21-25%) Rash (21-25%) Cough (15-20%) Dehydration (15-20%) URI (15-20%) Rigors, grade 4 toxicity (10-15%) Frequency Not Defined Hypotension Anxiety Pain Pruritis Abdominal pain Dyspepsia Back pain Bone pain Myalgia Muscle spasms Herpes zoster Pneumonia Blurred vision Potentially Fatal: Pneumonia, pyrexia, diarrhoea, vomiting, dehydration and nausea.

Mechanism of Action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26-S proteasome. It prevents targeted proteolysis that affects multiple signaling cascades responsible for normal homeostatic functions within the cell, leading to cell death.

Note

Bortenat 2mg Injection manufactured by Getwell Pharmaceuticals. Its generic name is Bortezomib. Bortenat is availble in Nepal. Farmaco Nepal drug index information on Bortenat Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Bortezomib :